TOP TEN perturbations for 1067_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1067_at
Selected probe(set): 210607_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1067_at (210607_at) across 6672 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-2.9946527
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):2.9229507
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):-2.7758398
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.6454525
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / ZSTK474 study 1 (10uM)

Relative Expression (log2-ratio):2.6080647
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control ZSTK474 study 1 (10uM)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with 10uM pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK434 for 6h. ATC code:---

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-2.5804148
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-2.5225658
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

PI3Kg inhibitor; GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):2.5179539
Number of Samples:10 / 10
Experimental PI3Kg inhibitor; GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with gamma phosphoinositide 3-kinase (PI3Kg) inhibitor and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-2.464429
Number of Samples:3 / 3
Experimental CAR T cell study 4 (GFP; post-infusion)
CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

septic shock study 1 (0h; SAPSII high) / normal blood sample

Relative Expression (log2-ratio):-2.4353027
Number of Samples:14 / 25
Experimental septic shock study 1 (0h; SAPSII high)
Blood samples from intensive care unit patients shortly after severe septic shock (SAPS II high). Severity was assessed using SAPS II score. The diagnosis of septic shock was based on the ACCP/SCCM criteria (1992). Septic shock was defined as the combination of SIRS and an infection. To be diagnosed with SIRS patients had to show at least two of the following clinical situation: hypothermia (<36°C) or hyperthermia (>38°C), tachycardia (>90/min), tachypnea (>20 breaths/min) and/or arterial PCO2 of 32 mmHg or lower and/or mechanical ventilation, and leukocytosis (>12,000/mm3) or leukopenia (<4,000/mm3). Septic shock was defined as acute circulatory failure (systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg, or a reduction in systolic blood pressure >40 mmHg from baseline). In order to avoid confounding effects, patients with human immunodeficiency syndrome, hematologic malignancies evolving from insulin-dependent diabetes, dialyzed chronic renal failure, chronic liver disease stages III and more or patients receiving immunosuppressive therapy were excluded from the study. Other clinical characteristics of the group: non-survivor (28.5%), charlson median (1.3-3.8 %), SAPS II on admission median (49-63), duration length in ICU median (6-30), SOFA H6 (9-13), admission (surgery: 57.1%; medical: 42.9%); type of infection (community acquired: 64.29%; hospital acquired: 35.71%), suspected infection (Bacilli Gram (-): 64%; Cocci Gram (+):64%; Fungi: 0%), cell counts (white blood cells: 3.23-15.68 giga/L; lymphocytes: 0.4-1.33; polymorphonuclear cells: 2.5-12.61; monocytes: 0.19-0.66).
Control normal blood sample
Blood samples from healthy volunteers.

Organism: Homo sapiens
Gene: 1067_at
Selected probe(set): 210607_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1067_at (210607_at) across 6672 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-2.9946527
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):2.9229507
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

T-cell activation study 3 / resting CD4 T-lymphocyte (crude fraction) sample

Relative Expression (log2-ratio):-2.7758398
Number of Samples:2 / 2
Experimental T-cell activation study 3
CD4+ T-cell samples prepared from crude lymphocyte fraction. Cells were activated with anti-CD3/28 beads for 18hrs.
Control resting CD4 T-lymphocyte (crude fraction) sample
Resting CD4 T-lymphocytes prepared from crude lymphocyte fraction.

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.6454525
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1 / ZSTK474 study 1 (10uM)

Relative Expression (log2-ratio):2.6080647
Number of Samples:10 / 10
Experimental ZSTK474 inhibitor (10uM); GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK474 (10uM) and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control ZSTK474 study 1 (10uM)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with 10uM pan phosphoinositide 3-kinase (PI3K) inhibitor ZSTK434 for 6h. ATC code:---

HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2) / HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)

Relative Expression (log2-ratio):-2.5804148
Number of Samples:3 / 3
Experimental HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-2.5225658
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

PI3Kg inhibitor; GM-CSF (1ng/ml) study 1 / mock treated neutrophils (6h)

Relative Expression (log2-ratio):2.5179539
Number of Samples:10 / 10
Experimental PI3Kg inhibitor; GM-CSF (1ng/ml) study 1
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with gamma phosphoinositide 3-kinase (PI3Kg) inhibitor and granulocyte macrophage-colony stimulating factor (rhGM-CSF; 1ng/ml) for 6h. ATC code:---
Control mock treated neutrophils (6h)
Primary neutrophils isolated from blood samples of healthy volunteers purified over discontinuous plasma-percoll gradients. Neutrophils were treated with DMSO for 6h.

CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-2.464429
Number of Samples:3 / 3
Experimental CAR T cell study 4 (GFP; post-infusion)
CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

septic shock study 1 (0h; SAPSII high) / normal blood sample

Relative Expression (log2-ratio):-2.4353027
Number of Samples:14 / 25
Experimental septic shock study 1 (0h; SAPSII high)
Blood samples from intensive care unit patients shortly after severe septic shock (SAPS II high). Severity was assessed using SAPS II score. The diagnosis of septic shock was based on the ACCP/SCCM criteria (1992). Septic shock was defined as the combination of SIRS and an infection. To be diagnosed with SIRS patients had to show at least two of the following clinical situation: hypothermia (<36°C) or hyperthermia (>38°C), tachycardia (>90/min), tachypnea (>20 breaths/min) and/or arterial PCO2 of 32 mmHg or lower and/or mechanical ventilation, and leukocytosis (>12,000/mm3) or leukopenia (<4,000/mm3). Septic shock was defined as acute circulatory failure (systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg, or a reduction in systolic blood pressure >40 mmHg from baseline). In order to avoid confounding effects, patients with human immunodeficiency syndrome, hematologic malignancies evolving from insulin-dependent diabetes, dialyzed chronic renal failure, chronic liver disease stages III and more or patients receiving immunosuppressive therapy were excluded from the study. Other clinical characteristics of the group: non-survivor (28.5%), charlson median (1.3-3.8 %), SAPS II on admission median (49-63), duration length in ICU median (6-30), SOFA H6 (9-13), admission (surgery: 57.1%; medical: 42.9%); type of infection (community acquired: 64.29%; hospital acquired: 35.71%), suspected infection (Bacilli Gram (-): 64%; Cocci Gram (+):64%; Fungi: 0%), cell counts (white blood cells: 3.23-15.68 giga/L; lymphocytes: 0.4-1.33; polymorphonuclear cells: 2.5-12.61; monocytes: 0.19-0.66).
Control normal blood sample
Blood samples from healthy volunteers.